All In Biotech

Free tool

FAERS Monitor: Cetrotide

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021197 or its brand name (Cetrotide, Cetrorelix Acetate). Reports on generic versions are filed under their own applications.

Reports

634

Serious

439

69% of reports

Hospitalization

218

Death reported

7

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • ovarian hyperstimulation syndrome136
  • drug ineffective45
  • premature ovulation41
  • abortion spontaneous39
  • abdominal distension30
  • off label use29
  • ascites28
  • abdominal pain26
  • condition aggravated25
  • nausea24
  • drug interaction21
  • generalised tonic-clonic seizure21
  • headache21
  • drug level decreased20
  • dizziness19

Reports by year received

View as table
YearReports
20052
20064
20078
20086
200916
20108
201117
201218
201316
201414
201533
201627
201755
201858
201994
202058
202134
202231
202332
202433
202530
202640

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,525 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
premature ovulationSignal4136797.423756.6698,278
ovarian hyperstimulation syndromeSignal1362055.61761.0261,110
drug level decreasedSignal2065.342.41,201
generalised tonic-clonic seizureSignal2142.227.7803
abortion spontaneousSignal3932.323.81,154
ascitesSignal2831.622.0800
abdominal distensionSignal309.56.7222
drug interactionSignal214.42.952
abdominal painSignal263.72.549
condition aggravatedSignal252.71.926
dizziness191.30.81
drug ineffective451.10.91
headache211.10.70
off label use291.10.80
nausea241.00.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.